Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virazole in Hospitalized COVID-19 Patients
NCT04356677Phase 1Withdrawn
- Sponsor
- Valeant Pharmaceuticals
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 1, open-label trial of ribavirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Change in clinical status severity rating at 7 days. Planned start May 2021; status: withdrawn.
02
Drugs
ribavirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04356677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356677.